Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Viking Therapeutics Stock Is Plunging Today

TheMotleyFool 
0 0 07.03.24
Why Viking Therapeutics Stock Is Plunging Today: https://g.foolcdn.com/editorial/images/768439/scales-with-feet.jpg
 

Shares of Viking Therapeutics (NASDAQ: VKTX) were plunging 17.4% lower as of 11:52 a.m. ET on Thursday. This decline wasn't caused by an announcement by Viking. Instead, the sell-off appears to be related to Novo Nordisk (NYSE: NVO) reporting results from a phase 1 study evaluating its experimental oral obesity drug amycretin.

Novo Nordisk revealed in an investor meeting on Thursday that patients receiving amycretin in its early-stage trial achieved an average weight loss of 13.1% after 12 weeks. This improvement matches the placebo-adjusted mean weight loss achieved by Viking's experimental obesity drug VK2735 in a phase 2 study. Viking announced those results last week.

Investors perceived Novo Nordisk's good news as potentially bad news for Viking. Why? VK2735 is administered subcutaneously, whereas amycretin is a pill. With similar efficacy results and greater convenience for patients, Novo Nordisk's drug could steal the thunder from VK2735.

Continue reading


Source Fool.com

Viking Therapeutics Inc Stock

€46.33
-0.980%
The price for the Viking Therapeutics Inc stock decreased slightly today. Compared to yesterday there is a change of -€0.460 (-0.980%).

Show more
Like: 0
VKTX
Share

Comments

Not a member yet? Sign up for free!